Status:
COMPLETED
Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-78 years
Phase:
PHASE3
Brief Summary
This study is not being conducted in the United States. Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to ass...
Eligibility Criteria
Inclusion
- On a stable dose of metformin as defined by the protocol
- Blood glucose criteria must be met
- Body mass index (BMI) in the range 22-45
Exclusion
- Pregnancy or lactation
- Type 1 diabetes
- Evidence of significant diabetic complications
- Evidence of serious cardiovascular complications
- Laboratory value abnormalities as defined by the protocol
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
1007 Patients enrolled
Trial Details
Trial ID
NCT00102466
Start Date
January 1 2005
End Date
January 1 2009
Last Update
December 17 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Centers
Nuremberg, Germany
2
Novartis Pharmaceuticals
Basel, Switzerland